<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04207255</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00095537</org_study_id>
    <secondary_id>1P01CA203628-01</secondary_id>
    <secondary_id>103193</secondary_id>
    <nct_id>NCT04207255</nct_id>
  </id_info>
  <brief_title>Addition of Opaganib to Androgen Antagonists in Patients With mCRPC</brief_title>
  <official_title>A Phase II Study of the Addition of Opaganib to Androgen Antagonists in Patients With Prostate Cancer Progression on Enzalutamide or Abiraterone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II study of the investigational drug opaganib. Patients with metastatic&#xD;
      castration resistant prostate cancer (mCRPC) who have experienced disease progression while&#xD;
      receiving abiraterone or enzalutamide will receive Opaganib at either 250 mg or 500 mg by&#xD;
      mouth twice a day continuously. Patients will continue on study drug until the development of&#xD;
      progressive disease, intolerable toxicity, withdrawal of patient consent or other event as&#xD;
      outlined in patient discontinuation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease control status</measure>
    <time_frame>113 days</time_frame>
    <description>Stable disease or better according to Prostate Cancer Working Group 3 (PCWG3) criteria after four cycles of treatment</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 2: Opaganib with abiraterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Opaganib with enzalutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1a: Opaganib with abiraterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1b: Opaganib with enzalutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Opaganib</intervention_name>
    <description>500mg of Opaganib orally twice a day continuously.</description>
    <arm_group_label>Cohort 2: Opaganib with abiraterone</arm_group_label>
    <arm_group_label>Cohort 3: Opaganib with enzalutamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone</intervention_name>
    <description>IV as directed by SOC</description>
    <arm_group_label>Cohort 1a: Opaganib with abiraterone</arm_group_label>
    <arm_group_label>Cohort 2: Opaganib with abiraterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>IV as directed by SOC</description>
    <arm_group_label>Cohort 1b: Opaganib with enzalutamide</arm_group_label>
    <arm_group_label>Cohort 3: Opaganib with enzalutamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Opaganib</intervention_name>
    <description>250mg of Opaganib orally twice a day continuously.</description>
    <arm_group_label>Cohort 1a: Opaganib with abiraterone</arm_group_label>
    <arm_group_label>Cohort 1b: Opaganib with enzalutamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient must have mCRPC. Each patient must have:&#xD;
&#xD;
               -  Tissue diagnosis documented by pathology report, or clinic note attesting to&#xD;
                  same.&#xD;
&#xD;
               -  Radiographically-demonstrated metastases&#xD;
&#xD;
               -  Patients must have adenocarcinoma, or ductal carcinoma, or combinations of these&#xD;
                  two entities&#xD;
&#xD;
          2. Voluntary, signed and dated, institutional review board (IRB)-approved informed&#xD;
             consent form in accordance with regulatory and institutional guidelines.&#xD;
&#xD;
          3. Documented progression during treatment with enzalutamide or abiraterone, as&#xD;
             determined by the enrolling investigator.&#xD;
&#xD;
          4. Testosterone level documented to be less than 50ng/&#xD;
&#xD;
          5. 18 years of age or older.&#xD;
&#xD;
          6. ECOG performance status of 0-2.&#xD;
&#xD;
          7. Acceptable liver function:&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 times upper limit of normal (CTCAE Grade 1 baseline)&#xD;
&#xD;
               -  AST (SGOT) &amp; ALT (SGPT) ≤ 3 x ULN (CTCAE Grade 1 baseline)&#xD;
&#xD;
               -  Subjects with Gilbert's syndrome may be included if the total bilirubin is &lt;3x&#xD;
                  ULN and the direct bilirubin is within normal limits&#xD;
&#xD;
          8. Acceptable kidney function indicated by serum creatinine ≤ 1.5 X ULN (CTCAE Grade 1&#xD;
             baseline)&#xD;
&#xD;
          9. Acceptable hematologic status:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1000 cells/mm3,&#xD;
&#xD;
               -  Platelet count ≥ 75,000 (plt/mm3) (CTCAE Grade 1 baseline)&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g/dL.&#xD;
&#xD;
         10. Fasting blood glucose of &lt;165mg/dL&#xD;
&#xD;
         11. Urinalysis: no clinically significant abnormalities&#xD;
&#xD;
         12. International normalized ratio (INR) ≤1.7&#xD;
&#xD;
         13. Well-controlled blood pressure as determined by the treating investigator&#xD;
&#xD;
         14. Patients requiring narcotic analgesics must be on stable doses for at least 2 weeks&#xD;
             prior to study entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. New York Heart Association Class III or IV, cardiac disease, myocardial infarction&#xD;
             within the past 6 months, unstable arrhythmia, or evidence of ischemia on ECG.&#xD;
&#xD;
          2. Underlying psychiatric disorder requiring hospitalization within the last two years.&#xD;
&#xD;
          3. Clinically significant neurological disorder (Parkinson's disease, dementia, multiple&#xD;
             sclerosis), as determined by the enrolling investigator.&#xD;
&#xD;
          4. Active, uncontrolled bacterial, viral or fungal infection, requiring systemic therapy.&#xD;
&#xD;
          5. Treatment with radiation therapy, surgery, or investigational therapy within 28 days&#xD;
             prior to registration.&#xD;
&#xD;
          6. Unwillingness or inability to comply with procedures required in this protocol.&#xD;
&#xD;
          7. Serious nonmalignant disease that could compromise protocol objectives in the opinion&#xD;
             of the Investigator.&#xD;
&#xD;
          8. Patients who are receiving coumadin, apixaban, argatroban or rivaroxaban. Patients who&#xD;
             are receiving other drugs that are sensitive substrates of CYP450 1A2, 3A4, 2C9, 2C19&#xD;
             or 2D6, or strong inhibitors or inducers of all major CYP450 isozymes that cannot be&#xD;
             stopped at least 7 days or 5 half-lives (whichever is longer) before starting&#xD;
             treatment with opaganib may be treated on this study with careful monitoring for toxic&#xD;
             effects or loss of efficacy of the relevant drug. A list of commonly used drugs that&#xD;
             are sensitive substrates of CYP450 1A2, 3A4, 2C9, 2C19 or 2D6, or strong inhibitors or&#xD;
             inducers of all major CYP450 isozymes with the half-life of each drug identified, is&#xD;
             included as an Appendix C.&#xD;
&#xD;
          9. Patients who are currently participating in any other clinical trial of an&#xD;
             investigational product.&#xD;
&#xD;
         10. Other primary malignancy requiring systemic treatment within past 5 years except&#xD;
             carcinoma in situ of the cervix or urinary bladder or non-melanoma skin cancer.&#xD;
&#xD;
         11. Any other mental incapacitation or psychiatric illness that would preclude study&#xD;
             participation, as determined by the enrolling investigator.&#xD;
&#xD;
         12. Prisoners or patients who are compulsorily detained (involuntarily incarcerated) for&#xD;
             treatment of either a psychiatric or physical (e.g., infectious disease) illness must&#xD;
             not be enrolled into this study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Lilly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alan Brisendine</last_name>
    <phone>843-792-9007</phone>
    <email>hcc-clinical-trials@musc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Lilly, MD</last_name>
    <phone>843-792-4271</phone>
    <email>lillym@musc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>20322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wilena Sessions</last_name>
      <email>wsessio@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Omer Kucuk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Brisendine</last_name>
      <phone>843-792-9007</phone>
      <email>hcc-clinical-trials@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Lilly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>December 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2019</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Yeliva</keyword>
  <keyword>ABC294640</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

